Sun Pharma Chief: We Are Not 'All In' In Biologics
CEO Remains 'Very Tentative,' Investment Still 'Very Large'
Executive Summary
Sun stays “tentative” about a large exposure in the biosimilars segment while also outlining its approach to commercialize some diverse pipeline assets including an early stage GLP-1 receptor agonist.
You may also be interested in...
Video Roundtable: APAC Team Talks Key Regional Trends And Topics
Join Scrip's APAC content team for a video overview of major trends and topics in the regional biopharma industry over the past few months.
Video Roundtable: APAC Team Talks Key Regional Trends And Topics
Join the Pink Sheet's APAC content team for a video overview of major trends and topics in the regional biopharma industry over the past few months.
Samsung Bioepis Responds To Rumor Of Biogen Biosimilars Buyout
Rumors of another major biosimilars deal are spreading after Korean media reported that Samsung Bioepis could be considering a bid for Biogen’s biosimilars business.